id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC6355556
core_pubmed_pmc
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis Abstract Invasive pulmonary aspergillosis (IPA) due to Aspergillus fumigatus is a serious fungal infection in the immunosuppressed patient population. Despite the introduction of new antifungal agents, mortality rates remain high, and new t...
PMC8671514
core_pubmed_pmc
Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats
Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats Abstract Abstract Up to a third of North Americans report using cannabis in the prior month, most commonly through inhalation. Animal models that reflec...
PMC12256568
core_pubmed_pmc
A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1‐3 Rearrangements
A Novel Empirical Autoinduction Model to Characterize the Population Pharmacokinetics and Recommend Dose for Repotrectinib in Adult and Adolescents With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1‐3 Rearrangements Abstract ABSTRACT Repotrectinib is approved in the US for treating ROS1‐positive non‐small cell lu...
PMC12364387
core_pubmed_pmc
Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden
Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden Abstract Pulmonary infection after inhalation of Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB). TB presents with lung granulomas – complex spheroidal structures composed ...
PMC4132488
core_pubmed_pmc
Review on Prescription Compatibility of Shaoyao Gancao Decoction and Reflection on Pharmacokinetic Compatibility Mechanism of Traditional Chinese Medicine Prescription Based on In Vivo Drug Interaction of Main Efficacious Components
Review on Prescription Compatibility of Shaoyao Gancao Decoction and Reflection on Pharmacokinetic Compatibility Mechanism of Traditional Chinese Medicine Prescription Based on In Vivo Drug Interaction of Main Efficacious Components Abstract Abstract Shaoyao Gancao Decoction (SGD) derived from Zhang Zhongjing's “Typhoi...
PMC6270907
core_pubmed_pmc
Pharmacokinetic Comparisons of Benzoylmesaconine in Rats Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry after Administration of Pure Benzoylmesaconine and Wutou Decoction
Pharmacokinetic Comparisons of Benzoylmesaconine in Rats Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry after Administration of Pure Benzoylmesaconine and Wutou Decoction Abstract Abstract Wutou decoction is widely used in China because of its therapeutic effect on rheumatoid arthritis. Benzoylm...
PMC6128565
core_pubmed_pmc
In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs
In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs Abstract The objective of this study was to investigate a possible mechanis...
PMC6848022
core_pubmed_pmc
Oral antenatal corticosteroids evaluated in fetal sheep
Oral antenatal corticosteroids evaluated in fetal sheep Abstract Abstract Background The use of antenatal corticosteroids (ACS) in low-resource environments is sporadic. Further, drug choice, dose, and route of ACS are not optimized. We report the pharmacokinetics and pharmacodynamics of oral dosing of ACS using a pret...
PMC12959160
core_pubmed_pmc
Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study
Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study Abstract ABSTRACT High-dose continuous infusion of cefepime is frequently employed in ICU patients with a creatinine cl...
PMC6978689
core_pubmed_pmc
Si-Ni-San Prevents Reserpine-Induced Depression by Inhibiting Inflammation and Regulating CYP450 Enzymatic Activity
Si-Ni-San Prevents Reserpine-Induced Depression by Inhibiting Inflammation and Regulating CYP450 Enzymatic Activity Abstract Depression is becoming a major public health concern worldwide. Si-Ni-San (SNS) is a famous formula in Traditional Chinese Medicine (TCM) with potent antidepressant effects. However, the antidepr...
PMC5753395
core_pubmed_pmc
SuperDRUG2: a one stop resource for approved/marketed drugs
SuperDRUG2: a one stop resource for approved/marketed drugs Abstract Abstract Regular monitoring of drug regulatory agency web sites and similar resources for information on new drug approvals and changes to legal status of marketed drugs is impractical. It requires navigation through several resources to find complete...
PMC12723595
core_pubmed_pmc
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis Abstract Key Points Question What are the long-term effects of early-start and placebo/delayed-start tofersen treatment in adults with SOD1 amyotrophic lateral sclerosis (ALS)? Findings This integrated analysis of the phase 3, randomized, double-blind, placebo-co...
PMC3765845
core_pubmed_pmc
Clinical experience with Zarzio® in Europe: what have we learned?
Clinical experience with Zarzio® in Europe: what have we learned? Abstract Abstract Biosimilars are similar, but non-identical, versions of existing biological drugs for which patents have expired. Despite the rigorous approval process for biosimilars, concerns have been expressed about the efficacy and safety of these...
PMC3513222
core_pubmed_pmc
Clinical implementation of RNA signatures for pharmacogenomic decision-making
Clinical implementation of RNA signatures for pharmacogenomic decision-making Abstract Abstract RNA profiling is increasingly used to predict drug response, dose, or toxicity based on analysis of drug pharmacokinetic or pharmacodynamic pathways. Before implementing multiplexed RNA arrays in clinical practice, validatio...
PMC4449375
core_pubmed_pmc
Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban Abstract Abstract Background and Objectives The effects of age and sex on apixaban pharmacokinetics and pharmacodynamics were studied. Methods This was an open-label, single-dose, 2 × 2 factorial study. Healthy young (aged 18–40...
PMC9540487
core_pubmed_pmc
Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations
Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations Abstract Abstract Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase ...
PMC6939748
core_pubmed_pmc
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma Abstract PURPOSE We sought to compare the pharmacokinetics (PKs) of DRL-rituximab (DRL_RI; potential biosimilar) and innovator rituximab MabThera (Roche, Grenzach-Wyhlen, Germ...
PMC12484309
core_pubmed_pmc
Assessing the Acceptability of a Tenofovir-Based Rectal Microbicide Douche among Young Men who Have Sex with Men: Results from ATN-DREAM (ATN 163)
Assessing the Acceptability of a Tenofovir-Based Rectal Microbicide Douche among Young Men who Have Sex with Men: Results from ATN-DREAM (ATN 163) Abstract Abstract Young men who have sex with men (YMSM) remain disproportionately affected by HIV, yet adherence to daily oral pre-exposure prophylaxis (PrEP) remains subop...
PMC6300238
core_pubmed_pmc
Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions
Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions Abstract Abstract Objective The research evaluated point-of-care drug interaction resources for scope, completeness, and consistency in drug-ethanol and drug-tobacco content. Methods In a cross-sectional analysis, 2 independent revi...
PMC4609166
core_pubmed_pmc
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Abstract Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glu...
PMC5374142
core_pubmed_pmc
Effect of CYP3A4 ∗ 1G and CYP3A5 ∗ 3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
Effect of CYP3A4 ∗ 1G and CYP3A5 ∗ 3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects Abstract Ticagrelor is the first reversible, direct-acting, potent P2Y 12 receptor antagonist in management of acute coronary syndromes. It is rapidly absorbed and extensively metabolize...
PMC11295620
core_pubmed_pmc
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer Abstract Background Elevated microRNA-155 (miR-155) expression in non-small-cell lung cancer (NSCLC) promotes cisplatin resistance and negatively impacts treatment ou...
PMC7732758
core_pubmed_pmc
Mini-Tablets versus Nanoparticles for Controlling the Release of Amoxicillin: In vitro/In vivo Study
Mini-Tablets versus Nanoparticles for Controlling the Release of Amoxicillin: In vitro/In vivo Study Abstract Abstract Introduction Controlling the drug release from the dosage form at a definite rate is the main challenge for a successful oral controlled-release drug delivery system. In this study, mini-tablets (MTs) ...
PMC11359992
core_pubmed_pmc
Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats
Population Pharmacokinetic–Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats Abstract (1) Background: Fibromyalgia syndrome (FMS) is a chronic pain condition with widespread pain and multiple comorbidities, for which conventional therapies offer limited benefits. The reserpine-induced myalgia (RIM) ...
PMC3394219
core_pubmed_pmc
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria Abstract Abstract Background Artemisinin-based combination therapy (ACT) is currently recommended as first-line treatment for uncomplicated malaria, ...
PMC8646568
core_pubmed_pmc
Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction
Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction Abstract Abstract Remdesivir, a prodrug of the nucleoside analog GS‐441524, plays a key role in the treatment of coronavirus disease 2019 (COVID‐19). However, owing to limited info...
PMC10301001
core_pubmed_pmc
Radiochemical and Biological Evaluation of 3p- C -NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
Radiochemical and Biological Evaluation of 3p- C -NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics Abstract Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic radionuclides, a theranostic pa...
PMC6989222
core_pubmed_pmc
Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults
Population pharmacokinetic analysis of metformin administered as fixed-dose combination in Korean healthy adults Abstract Metformin, an oral antihyperglycemic agent, is widely used as the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM). It has been in use for several decades as numerous different formula...
PMC12889215
core_pubmed_pmc
Differences in International Recommendations for Piperacillin Dosing: A Japanese Perspective
Differences in International Recommendations for Piperacillin Dosing: A Japanese Perspective Abstract Abstract Differences in antibiotic dosing recommendations highlight the tension between maximizing efficacy and ensuring safety. Piperacillin is a striking example, with the Sanford Guide recommending regimens of 13.5-...
PMC12058161
core_pubmed_pmc
The plant matrix of Artemisia annua L. for the treatment of malaria: Pharmacodynamic and pharmacokinetic studies
The plant matrix of Artemisia annua L. for the treatment of malaria: Pharmacodynamic and pharmacokinetic studies Abstract Artemisinin-based combination therapies (ACTs) constitute the principal strategy for combating malaria in contemporary times, and research into the multifaceted components of Artemisia annua L. ( A....
PMC9562568
core_pubmed_pmc
High initial target blood concentration in target‐controlled infusion: A randomized controlled trial
High initial target blood concentration in target‐controlled infusion: A randomized controlled trial Abstract Abstract Objective Our previously modified propofol intravenous sedation (IVS) method using a target‐controlled infusion (TCI) pump with initial target blood concentration (TBC) set at 2.2 μg/ml enables the pre...
PMC5515635
core_pubmed_pmc
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions
A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions Abstract The US Food and Drug Administration (FDA) issued a guidance document in 2010 on pharmacokinetic (PK) studies in renal impairment (RI) ...
PMC7579418
core_pubmed_pmc
Pharmacokinetics of Ketoprofen in Nile Tilapia ( Oreochromis niloticus ) and Rainbow Trout ( Oncorhynchus mykiss )
Pharmacokinetics of Ketoprofen in Nile Tilapia ( Oreochromis niloticus ) and Rainbow Trout ( Oncorhynchus mykiss ) Abstract Abstract The objective of this study was to document the pharmacokinetics of ketoprofen following 3 mg/kg intramuscular (IM) and intravenous (IV) injections in rainbow trout ( Oncorhynchus mykiss ...
PMC10042915
core_pubmed_pmc
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review Abstract Background and Objective Quantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treat...
PMC6064159
core_pubmed_pmc
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty
The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty Abstract Background Non-vitamin K oral anticoagulants (NOACs) are commonly used for prophylaxis of venous thromboembolism (VTE) in orthopedic patie...
PMC12358563
core_pubmed_pmc
A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer
A novel solid phase synthesis of an estradiol derivative and preclinical evaluation for targeting estrogen-receptor positive breast cancer Abstract [ 18 F]-Fluoroestradiol, which is recently approved by the FDA, is a well-recognized estrogen receptor radiopharmaceutical in nuclear medicine to investigate both primary a...
PMC6123365
core_pubmed_pmc
Pharmacokinetics of Nuciferine and N-Nornuciferine, Two Major Alkaloids From Nelumbo nucifera Leaves, in Rat Plasma and the Brain
Pharmacokinetics of Nuciferine and N-Nornuciferine, Two Major Alkaloids From Nelumbo nucifera Leaves, in Rat Plasma and the Brain Abstract The leaf of the lotus ( Nelumbo nucifera ) is a natural plant resource used as both food and herbal medicine (He-Ye) in China. Alkaloids are considered the major bioactive compound ...
PMC10509224
core_pubmed_pmc
Exploration of CviR-mediated quorum sensing inhibitors from Cladosporium spp. against Chromobacterium violaceum through computational studies
Exploration of CviR-mediated quorum sensing inhibitors from Cladosporium spp. against Chromobacterium violaceum through computational studies Abstract Abstract An opportunistic human pathogenic bacterium, Chromobacterium violaceum resists the potency of most antibiotics by exploiting the quorum sensing system within th...
PMC6836259
core_pubmed_pmc
Pharmacokinetics and Novel Metabolite Identification of Tartary Buckwheat Extracts in Beagle Dogs Following Co-Administration with Ethanol
Pharmacokinetics and Novel Metabolite Identification of Tartary Buckwheat Extracts in Beagle Dogs Following Co-Administration with Ethanol Abstract Alcoholic liver disease (ALD) has become a critical global public health issue worldwide. Tartary buckwheat extracts exhibit potential therapeutic effects against ALD due t...
PMC8098993
core_pubmed_pmc
ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial
ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial Abstract Abstract Introduction The unfavourable influence of morphine on the pharmacokinetics...
PMC6093847
core_pubmed_pmc
Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy
Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy Abstract Abstract Objective This double‐blind, randomized, placebo‐controlled Phase 2 study ( NCT 01462292) assessed the 24‐week efficacy, safety, tolerability, and pharmacokinetics of two different subcutaneous drisapersen doses, and the 2...
PMC4939996
core_pubmed_pmc
Effect of N -methyl deuteration on metabolism and pharmacokinetics of enzalutamide
Effect of N -methyl deuteration on metabolism and pharmacokinetics of enzalutamide Abstract Abstract Background The replacement of hydrogen with deuterium invokes a kinetic isotope effect. Thus, this method is an attractive way to slow down the metabolic rate and modulate pharmacokinetics. Purpose Enzalutamide (ENT) ac...
PMC7070790
core_pubmed_pmc
Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study Abstract Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop ...
PMC4505827
core_pubmed_pmc
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models Abstract Target-mediated drug disposition (TMDD) is the phenomenon in which a drug binds with high affinity to its pharmacological target site (such as a receptor) to such an extent that this affects its pharmacokinetic characteristics. 1 The aim of this Tuto...
PMC10582654
core_pubmed_pmc
Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020 Abstract Abstract Deriving pediatric doses for locally acting drugs (LADs) presents a unique challenge because limited systemic exposure hinders commonly used approaches such as pharmacokinetic matchi...
PMC12655228
core_pubmed_pmc
Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies
Recent Progress on Affibody-Based Supramolecular Architectures: Moving from Monomeric Constructs to Multivalent Assemblies Abstract Abstract Affibody molecules have emerged as versatile protein engineering platforms due to their exceptional binding properties. These small (6.5 kDa) three-helix bundle proteins, derived ...
PMC11539228
core_pubmed_pmc
Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome
Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome Abstract Highlights • aHUS is a rare complement disease, leading to TMA. • eculizumab is a lifelong therapy burdened with high costs and increased infection risk. • personalised dosing strategy (PDS) is strongly advised. • PDS ...
PMC7719385
core_pubmed_pmc
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non‐Small Cell Lung Cancer Harboring Only EGFR Mutations
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non‐Small Cell Lung Cancer Harboring Only EGFR Mutations Abstract The recommended daily dose of erlotinib was determined for patients with all types of non‐small cell lung cancer (NSCLC). We determined the optimal dose (OD) in patients with NS...
PMC9298614
core_pubmed_pmc
Determination of sulfamonomethoxine in tilapia ( Oreochromis niloticus × Oreochromis mossambicus ) by liquid chromatography-tandem mass spectrometry and its application pharmacokinetics study
Determination of sulfamonomethoxine in tilapia ( Oreochromis niloticus × Oreochromis mossambicus ) by liquid chromatography-tandem mass spectrometry and its application pharmacokinetics study Abstract A precise and reliable analytical method to measure trace levels of sulfamonomethoxine (SMM) and N 4 -acetyl metabolite...
PMC5698807
core_pubmed_pmc
High‐Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin
High‐Performance Liquid Chromatography Method for Rich Pharmacokinetic Sampling Schemes in Translational Rat Toxicity Models With Vancomycin Abstract Abstract A translational need exists to understand and predict vancomycin‐induced kidney toxicity. We describe: (i) a vancomycin high‐performance liquid chromatography (H...
PMC8528144
core_pubmed_pmc
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease Abstract Abstract Background The association between vedolizumab (VDZ) exposure and treatment response is unclear and seems insufficiently explained by serum levels. The aim of this study w...
PMC3487491
core_pubmed_pmc
Effects of Berberine and Hwangryunhaedok-Tang on Oral Bioavailability and Pharmacokinetics of Ciprofloxacin in Rats
Effects of Berberine and Hwangryunhaedok-Tang on Oral Bioavailability and Pharmacokinetics of Ciprofloxacin in Rats Abstract Abstract Hwangryunhaedok-Tang (HR) and berberine-containing single herbs are used to treat bacterial infection and inflammatory diseases in eastern Asia. The combination of berberine-containing h...
PMC5286730
core_pubmed_pmc
Sex differences in the psychopharmacological treatment of depression
Sex differences in the psychopharmacological treatment of depression Abstract Abstract Although a number of studies have observed that females respond better to serotonergic antidepressants than males and that postmenopausal females have a diminished response to antidepressants compared with younger females, there are ...
PMC4050233
core_pubmed_pmc
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis Abstract Abstract Population modeling of tumor size dynamics has recently emerged as an important tool in pharmacometric research. A series of new mixed-effects models have been reported recently, and w...
PMC6682573
core_pubmed_pmc
Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review
Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review Abstract Abstract Purpose Vincristine is widely used as anticancer therapy for a variety of hematological malignancies. The treatment is limited by progressive vincristine-induced neuropathy, possibly including both peripheral se...
PMC10068419
core_pubmed_pmc
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions?
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions? Abstract Abstract Background Standard antibiotic dosing is not suitable for critically ill patients, due to altered pharmacokinetics (PK) in these patients. Knowledge of protein binding is important for optimizing antibi...
PMC8299834
core_pubmed_pmc
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials Abstract Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), not...
PMC7549803
core_pubmed_pmc
Quantifying the probability of pharmacological success to inform compound progression decisions
Quantifying the probability of pharmacological success to inform compound progression decisions Abstract Abstract The Probability of Pharmacology Success, or PoPS, is a powerful metric to inform progression decisions by quantifying a compound’s overall pharmacological strength based on its mechanism. It is defined as t...
PMC4269813
core_pubmed_pmc
Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function Abstract Introduction Approximately one-third of patients with type 2 diabetes mellitus (T2DM) have concurrent renal impairment. There are limited therapeutic options f...
PMC7280087
core_pubmed_pmc
Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats Abstract Purpose The purpose of this study was to examine the effects of voriconazole on the pharmacokinetics of vonoprazan. Methods Fifteen Sprague-Dawley rats were randomly divided into three groups: five rats in each group, including control group...
PMC7938371
core_pubmed_pmc
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial Abstract Abstract Objectives The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, ...
PMC11517514
core_pubmed_pmc
Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study
Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: In vitro and in vivo pharmacokinetic study Abstract Abstract Background and purpose Sorafenib tosylate (SFN), a potent multikinase inhibitor, is used for the treatment of various cancer...
PMC8536579
core_pubmed_pmc
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer Abstract Abstract Purpose To evaluate the pharmacodynamics (PD), pharmacokinetics (PK), and safety of single and multiple doses of PF-06...
PMC8896685
core_pubmed_pmc
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls Abstract During recent years combining GLP-1 and glucagon receptor agonism with the purpose of achieving superior weight loss and metabolic control compared to GLP-1 alone has received much attention. The ...
PMC8037743
core_pubmed_pmc
Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation
Polymerized Whey Protein Concentrate-Based Glutathione Delivery System: Physicochemical Characterization, Bioavailability and Sub-Chronic Toxicity Evaluation Abstract Glutathione (GSH) is a powerful antioxidant, but its application is limited due to poor storage stability and low bioavailability. A novel nutrient encap...
PMC9657224
core_pubmed_pmc
Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion
Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion Abstract Abstract The aim of the study was the development and validation of the UHPLC-QqQ-MS/MS method for the determination of mifepristone in human blood as well as the identification and quantification...
PMC12426043
core_pubmed_pmc
Unraveling the HIV-malaria interactions: a bibliometric analysis of global research trends and emerging insights
Unraveling the HIV-malaria interactions: a bibliometric analysis of global research trends and emerging insights Abstract Background The co-infection of human immunodeficiency virus (HIV) and malaria has emerged as an urgent public health challenge in tropical areas where the two diseases geographically converge, stimu...
PMC8316195
core_pubmed_pmc
Penetration of echinocandins into wound secretion of critically ill patients
Penetration of echinocandins into wound secretion of critically ill patients Abstract Purpose Wound infections caused by Candida are life-threatening and difficult to treat. Echinocandins are highly effective against Candida species and recommended for treatment of invasive candidiasis. As penetration of echinocandins ...
PMC7716890
core_pubmed_pmc
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine
Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine Abstract Background and Objective A novel cocktail containing four substrates of key drug transporters was previously optimized to eliminate mutual drug–drug interactions between the probes ...
PMC6130524
core_pubmed_pmc
Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats
Effects of type 2 diabetes mellitus on the pharmacokinetics of berberine in rats Abstract Abstract Context: Berberine is an active alkaloid isolated from Rhizoma coptidis [ Coptis chinensis Franch. (Ranunculaceae)] that is widely used for the treatment of diabetes, hyperlipidemia and hypertension. However, the pharmaco...
PMC12572147
core_pubmed_pmc
Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment
Meropenem dosing optimization on day 1 and steady state in critically ill patients without significant renal impairment Abstract This study aimed to characterize meropenem pharmacokinetics and optimise dosing for the initial and steady state in critically ill patients. Adult patients receiving meropenem were recruited,...
PMC8930270
core_pubmed_pmc
Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions
Quantitation of Diclofenac, Tolbutamide, and Warfarin as Typical CYP2C9 Substrates in Rat Plasma by UPLC-MS/MS and Its Application to Evaluate Linderane-Mediated Herb-Drug Interactions Abstract Abstract Linderane (LDR), the main active and distinctive component of L. aggregate , is a mechanism-based inactivator of CYP2...
PMC12936905
core_pubmed_pmc
Tumor visualization and evaluation of glioblastoma in mice using small animal 9.4T MRI and PET-CT with high resolution
Tumor visualization and evaluation of glioblastoma in mice using small animal 9.4T MRI and PET-CT with high resolution Abstract Abstract Glioblastoma (GBM) is the most prevalent type of malignant primary brain tumor. Preclinical research serves a key role in investigating the development and mechanism of GBM tumor. How...
PMC6722145
core_pubmed_pmc
A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers
A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic profiles of cigarettes and e-cigarettes with nicotine salt formulations in US adult smokers Abstract E-cigarettes containing ‘nicotine salts’ aim to increase smoker’s satisfaction by improving blood nicotine delivery and other sensory p...
PMC4439876
core_pubmed_pmc
Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat
Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat Abstract Background and Purpose The effects of ketamine in attenuating morphine tolerance have been suggested to result from a pharmacodynamic interaction. We studied whether ketamine might incre...
PMC9742883
core_pubmed_pmc
Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice
Safety, toxicity and pharmacokinetic assessment of oral Withaferin-A in mice Abstract Abstract Withaferin-A (WA) is the principle component of Withania somnifera (Ashwagandha). It has several biological activities including anti-cancer, anti-diabetic, neuroprotective, hepatoprotective and immune-modulatory properties. ...
PMC3016151
core_pubmed_pmc
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors Abstract Summary Purpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor ( KDR; VEGFR-2 ) and fms-related tyrosine kinase 4 ( FLT4; VEGFR-3 ). This s...
PMC12257270
core_pubmed_pmc
Phenotype‐Specific Semi‐Mechanistic Modelling of Florfenicol Time‐Kill Curves in G. Parasuis Compared to Other Respiratory Pathogens
Phenotype‐Specific Semi‐Mechanistic Modelling of Florfenicol Time‐Kill Curves in G. Parasuis Compared to Other Respiratory Pathogens Abstract ABSTRACT This study examines the pharmacodynamics (PD) of florfenicol (FFN) for treating porcine respiratory diseases by comparing its effects on Glaesserella parasuis , Actinoba...
PMC12204083
core_pubmed_pmc
Transdermal microneedle integrating a biomimetic self-enhancing Fenton reaction nano-reactor for alleviating rheumatoid arthritis by inflammatory microenvironment remodeling
Transdermal microneedle integrating a biomimetic self-enhancing Fenton reaction nano-reactor for alleviating rheumatoid arthritis by inflammatory microenvironment remodeling Abstract Abstract Rationale: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, and persistent inflammation in multiple joint...
PMC11015081
core_pubmed_pmc
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach Abstract Abstract Brigatinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK ‐positive metastatic non‐small cell lung cancer. In vitro studies indicated...
PMC11919262
core_pubmed_pmc
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries Abstract ABSTRACT Enhanced Recovery After Surgery (ERAS) protocols for cesarean deliveries (CDs) utilize multimodal pain management strategies that often include gabapentin. While gabapentin is excreted in breast ...
PMC8954739
core_pubmed_pmc
Correlating Mass Spectrometry Imaging and Liquid Chromatography-Tandem Mass Spectrometry for Tissue-Based Pharmacokinetic Studies
Correlating Mass Spectrometry Imaging and Liquid Chromatography-Tandem Mass Spectrometry for Tissue-Based Pharmacokinetic Studies Abstract Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a standard tool used for absolute quantification of drugs in pharmacokinetic (PK) studies. However, all spatial informat...
PMC9323444
core_pubmed_pmc
Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product
Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product Abstract Botulism antitoxin heptavalent (A, B, C, D, E, F, and G – Equine; BAT) product is a sterile solution of F(ab') 2 and F(ab') 2 ‐related antibody fragments prepared from plasma obtained from horses that ha...
PMC9540432
core_pubmed_pmc
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus Abstract Abstract We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor–blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenou...
PMC10272302
core_pubmed_pmc
Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia Abstract Abstract Despite the potential for efavirenz (EFV) to be an effective alternative antiretroviral agent, its sources of wide inter‐ and intra‐individual pharmacoki...
PMC9880024
core_pubmed_pmc
A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors
A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors Abstract Abstract Immune checkpoint inhibitors (ICIs) have been shown to be significant in improving the overall survival rate in certain malignancies with poor prognoses. However, only 20–40% of patients a...
PMC10349197
core_pubmed_pmc
Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies
Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies Abstract Abstract In a traditional pharmacokinetic (PK) bioequivalence (BE) study, a two‐way crossover study is conducted, PK parameters (namely the area under the time‐concentration curve [AUC] and the maximal concentration [ C...
PMC7290329
core_pubmed_pmc
A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear)
A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear) Abstract Abstract Medium cut-off membrane (MCO) dialysers have been shown to remove a range of middle molecules, which are associated with adverse outcomes in ...
PMC12024483
core_pubmed_pmc
Bioequivalence and Food Effect Assessment of Two Fixed‐Dose Combination Formulations of Telmisartan‐Hydrochlorothiazide Tablets in Chinese Healthy Subjects
Bioequivalence and Food Effect Assessment of Two Fixed‐Dose Combination Formulations of Telmisartan‐Hydrochlorothiazide Tablets in Chinese Healthy Subjects Abstract ABSTRACT This study assessed the bioequivalence and food effect of two fixed‐dose combination (FDC) formulations of telmisartan‐hydrochlorothiazide tablets...
PMC8504815
core_pubmed_pmc
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial Abstract Abstract Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the hum...
PMC12517015
core_pubmed_pmc
Liposomal bupivacaine versus ropivacaine perianal infiltration for postoperative analgesia of haemorrhoidectomy: a multicentre, randomised controlled trial
Liposomal bupivacaine versus ropivacaine perianal infiltration for postoperative analgesia of haemorrhoidectomy: a multicentre, randomised controlled trial Abstract Abstract Objectives To evaluate whether liposomal bupivacaine provides superior postoperative analgesia compared with ropivacaine following haemorrhoidecto...
PMC7496893
core_pubmed_pmc
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function Abstract Abstract Peficitinib (ASP015K) is a novel Janus kinase inhibitor developed for the treatment of rheumatoid arthritis (RA). The impact of hepatic impairment on the peficitini...
PMC12648066
core_pubmed_pmc
Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial
Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial Abstract ABSTRACT Background and hypothesis Despite benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) being recommended for treatment of chronic kidney disease (CKD), there is still an u...
PMC6951491
core_pubmed_pmc
Temperature and eluent composition effects on enantiomer separation of carvedilol by high-performance liquid chromatography on immobilized amylose-based chiral stationary phases
Temperature and eluent composition effects on enantiomer separation of carvedilol by high-performance liquid chromatography on immobilized amylose-based chiral stationary phases Abstract Carvedilol is a chiral drug with potent antihypertensive and antianginal activities. Although it is clinically used as a racemic mixt...
PMC5354542
core_pubmed_pmc
An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch
An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch Abstract We investigated the pharmacokinetics and safety profiles of a newly developed combined ethinylestradiol (EE)/gestodene (GSD) transdermal contraceptive patch after ...
PMC9579381
core_pubmed_pmc
Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis Abstract Abstract The pharmacokinetics (PKs) and exposure–efficacy of dupilumab have not been fully described for adults with atopic dermatitis (AD). Our objectives were to analyze the PKs and exposure–efficacy of du...
PMC12115004
core_pubmed_pmc
The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review
The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review Abstract Background/Objectives : Methadone maintenance treatment (MMT) is widely used in opioid use disorder (OUD). Its efficacy is influenced by its metabolism, primarily mediated by Cytochrome P450 (CYP450) enzymes in ...
PMC12151077
core_pubmed_pmc
Rapid Replenishment of Phylloquinone in the Plasma and Liver Using Hyaluronan-Based Nanocapsules Reverses Endothelial Dysfunction in Mice
Rapid Replenishment of Phylloquinone in the Plasma and Liver Using Hyaluronan-Based Nanocapsules Reverses Endothelial Dysfunction in Mice Abstract Introduction As vitamin K 1 (phylloquinone, PK) displays vasoprotective effect, low dietary intake and poor bioavailability of PK may result in insufficient systemic levels ...
PMC11515805
core_pubmed_pmc
Drug-gene interactions in older patients with coronary artery disease
Drug-gene interactions in older patients with coronary artery disease Abstract Background Older patients with coronary artery disease (CAD) are particularly vulnerable to the efficacy and adverse drug reactions, and may therefore particularly benefit from personalized medication. Drug–gene interactions (DGIs) occur whe...
PMC5613179
core_pubmed_pmc
Pharmacokinetics of Monoclonal Antibodies
Pharmacokinetics of Monoclonal Antibodies Abstract Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical...